Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
P/E Ratio
0
P/B Ratio
15.1
Industry P/E
37.44
Debt to Equity
0
ROE
-5.84 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
2.04
CFO
$-247.05 Mln
EBITDA
$-300.14 Mln
Net Profit
$-308.32 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
| -98.88 | -- | -91.60 | -99.00 | -93.16 | -78.74 | -73.66 |
|
BSE Sensex*
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
| -93.18 | -58.28 | 3.16 | 17.91 | -76.74 | -89.44 | 41.54 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 63.50 | 11,522.38 | -- | -11.55 |
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an... intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Read more
Founder, Chairman, CEO & President
Dr. Raj Mehra J.D., Ph.D.
Founder, Chairman, CEO & President
Dr. Raj Mehra J.D., Ph.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Seelos Therapeutics Inc (SEEL) stood at $ 33 Mln as on 30-Jun-24
The share price of Seelos Therapeutics Inc (SEEL) is $0.25 (NASDAQ) as of 17-Dec-2024 09:30 EDT. Seelos Therapeutics Inc (SEEL) has given a return of -93.16% in the last 3 years.
Seelos Therapeutics Inc (SEEL) has a market capitalisation of $ 0 Mln as on 17-Dec-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Seelos Therapeutics Inc (SEEL) is 15.10 times as on 17-Dec-2024, a 200% premium to its peers’ median range of 5.04 times.
Since, TTM earnings of Seelos Therapeutics Inc (SEEL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Seelos Therapeutics Inc (SEEL) and enter the required number of quantities and click on buy to purchase the shares of Seelos Therapeutics Inc (SEEL).
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
The CEO & director of Dr. Raj Mehra J.D., Ph.D.. is Seelos Therapeutics Inc (SEEL), and CFO & Sr. VP is Dr. Raj Mehra J.D., Ph.D..
There is no promoter pledging in Seelos Therapeutics Inc (SEEL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,152
|
| Seelos Therapeutics Inc. (SEEL) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-1480.73
|
|
Net Margin(%)
|
203.13
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Seelos Therapeutics Inc (SEEL) was $0 Mln.
$-0.92
(
